Cutaneous adverse reactions associated with medications for movement disorders: a narrative review
نویسندگان
1 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Clinical Research Development Unit, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
8 Skin Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
doi
10.22034/ijd.2024.458351.1850چکیده
Movement disorders are characterized by either an excess of movement or a deficiency in voluntary and automatic movements. Medications prescribed for these disorders can lead to a range of cutaneous adverse events. This study provides a comprehensive review of such cutaneous reactions. Our objective is to evaluate the cutaneous adverse reactions associated with medications used to treat movement disorders. We conducted a search of medical databases using relevant keywords and assessed studies that detailed specific drug-related cutaneous complications. We categorized movement disorders into two main types: hypokinetic and hyperkinetic. In the context of hypokinetic movement disorders, we examined various treatment modalities, including dopaminergic agents, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase-B (MAO-B) inhibitors, anticholinergics, aromatic L-amino acid decarboxylase inhibitors, amantadine, and deep brain stimulation. We also evaluated the associated cutaneous adverse reactions of these treatments. We also reviewed the cutaneous complications associated with medications used to treat hyperkinetic disorders, including antipsychotics, antiepileptics, mood stabilizers, botulinum toxins, clonidine, guanfacine, cyclobenzaprine, baclofen, orphenadrine, chelators, beta-blockers, and anti-dementia drugs. Various types of cutaneous adverse events have been reported with these medications. It is essential for all physicians, particularly general practitioners and neurologists, to be aware of these complications, especially severe adverse events such as angioedema, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
